Patents Represented by Attorney, Agent or Law Firm Patricia S. Rocha
-
Patent number: 6835732Abstract: The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.Type: GrantFiled: December 5, 2002Date of Patent: December 28, 2004Assignee: Hoffman-La Roche Inc.Inventors: Alexander Alanine, Alexander Flohr, Aubry Kern Miller, Roger David Norcross, Claus Riemer
-
Patent number: 6831087Abstract: The invention relates to compounds of formulae: Compounds of the invention have a good affinity to the NMDA receptor and are useful for the treatment of diseases related to this receptor.Type: GrantFiled: October 29, 2002Date of Patent: December 14, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, Rene Wyler
-
Patent number: 6827907Abstract: A compound handling system handles a multiplicity of chemical or biological compounds or samples, and is especially adapted for high throughput screening of compounds that are stored and handled in aliquotted form. Aliquots are contained in individual containers and the containers are arranged in racks having holding spaces open at opposite ends. Insertion and removal of the containers is effected in either direction of movement, and each container may be sealed with foil to protect its integrity.Type: GrantFiled: December 20, 2000Date of Patent: December 7, 2004Assignee: Hoffmann-LA Roche Inc.Inventors: Christof Fattinger, Hansjörg Tschirky
-
Patent number: 6818663Abstract: The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung and colon and prostate tumors.Type: GrantFiled: May 5, 2003Date of Patent: November 16, 2004Assignee: Hoffmann-La RochesInventors: Xin-Jie Chu, Qingjie Ding, Nan Jiang, Kyungjin Kim, Allen John Lovey, Warren William McComas, John Guifoyle Mullin, Jr., Jefferson Wright Tilley
-
Patent number: 6818774Abstract: Disclosed are isoquinolino derivatives of the formula wherein Y is >C═O or —CH2—, Z is >C═O or —CH2—, and R1, R2 and m are as defined herein as well as the pharmaceutically acceptable salts thereof. These compounds are MAO-B selective inhibitors useful, inter alia, in the treatment of Alzheimer's disease and/or senile dementia.Type: GrantFiled: April 16, 2003Date of Patent: November 16, 2004Assignee: Hoffman-La Roche Inc.Inventors: Andrea Cesura, Rosa Maria Rodriguez Sarmiento, Michelangelo Scalone, Andrew William Thomas, Rene Wyler
-
Patent number: 6806370Abstract: Compounds of the invention are amine oxide prodrugs showing activity on the NK1 receptor.Type: GrantFiled: August 21, 2003Date of Patent: October 19, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Torsten D. Hoffmann, Sonia Maria Poli, Patrick Schnider, Andrew Sleight
-
Patent number: 6803381Abstract: The present invention relates to compounds of formula wherein R1 is hydrogen or lower alkyl; R2, R2′ are each independently hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; X is O, S or two hydrogen atoms not forming a bridge; A1/A2 is phenyl; B is a group of formula wherein R3 is lower alkyl, lower alkenyl, lower alkinyl, benzyl, lower alkyl-cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl, lower alkyl-lower alkoxy-phenyl, lower alkyl-phenyl, which is optionally substituted by lower alkoxy, or phenyl, which is optionally substituted by lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower alkyl-trifluoromethyl or lower alkyl-morpholinyl; Y is —O—, —S— or a bond; and Z is —O—; or a pharmaceutically acceptable salt thereof. These compounds are useful for the control or prevention of acute and/or chronic neurological disorders.Type: GrantFiled: May 14, 2003Date of Patent: October 12, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Konrad Bleicher, Vincent Mutel, Eric Vieira, Jürgen Wichmann, Thomas Johannes Woltering
-
Patent number: 6800638Abstract: A compound of the formula (I) wherein A, R1, R2 and X have the meanings defined in the specification, process of manufacturing such as compound and a pharmaceutical composition with HDAC inhibitor activity and anti-cell proliferation activity containing such a compound.Type: GrantFiled: June 23, 2003Date of Patent: October 5, 2004Assignee: Hoffman-La Roche Inc.Inventors: Guy Georges, Adelbert Grossman, Olaf Mundigl, Wolfgang von der Saal, Tim Sattelkau
-
Patent number: 6794139Abstract: A pharmaceutical composition is disclosed, as well as its use in tumour diagnosis, therapy and prevention, methods for diagnosing, treating and preventing tumours, and antibodies and their use.Type: GrantFiled: October 24, 2001Date of Patent: September 21, 2004Assignee: Roche Diagnostics GmbHInventors: Sabine Schiemann, Ulrich Weidle
-
Patent number: 6790852Abstract: The invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and related diseases.Type: GrantFiled: April 7, 2003Date of Patent: September 14, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Michael Brandt, Georg Fertig, Hans-Willi Krell, Thomas von Hirschheydt, Edgar Voss
-
Patent number: 6787539Abstract: The invention relates to compounds of the formula wherein R1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, —S-lower alkyl, —S(O)2-lower alkyl, —N(R)—(CH2)n—N(R)2, —O—(CH2)n—N(R)2, —N(R)2, or a cyclic tertiary amine of the group which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker —O(CH2)n—; R2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R3/R3′ is, independently from each other, hydrogen or lower alkyl; R4 is independently from each other halogen, trifluoromethyl or lower alkoxy; R5 is hydrogen or lower alkyl; R is, independently from each other, hydrogen or lower alkyl; X is —C(O)N(R)— or —N(R)C(O)—; Y is —O—, —S—, —SO2—, - or —N(R)—; n is 1,2,3 or 4; and m is 0,1 or 2; or a pharmaceuticType: GrantFiled: October 15, 2001Date of Patent: September 7, 2004Assignee: Hoffmann-La Roche Inc.Inventor: Heinz Stadler
-
Patent number: 6784173Abstract: Compounds of formula I wherein A, R1 and R2 are defined in the specification. These compounds are useful as HDAC inhibitors. Also disclosed are methods of making and using said compounds.Type: GrantFiled: June 11, 2002Date of Patent: August 31, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Ulrike Leser-Reiff, Tim Sattelkau, Gerd Zimmermann
-
Patent number: 6770637Abstract: Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.Type: GrantFiled: August 3, 2001Date of Patent: August 3, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Thierry Godel, Torsten Hoffmann, Patrick Schnider, Heinz Stadler
-
Patent number: 6762320Abstract: This invention relates to N-acylamino aryl derivatives of the formula where R1, R21, R22, R23, R24, R3, R4, R5 R6, R7, R8, R, and n are as defined herein and where X is —CHRO, —OCHR—, —CH2S—, —SCH2—, —CH2CH2—, —CH═CH— or —C≡C—. The compounds of the invention are selective monoamine oxidase B inhibitors, and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B, for example, for the treatment of Alzheimer's disease or senile dementia.Type: GrantFiled: May 27, 2003Date of Patent: July 13, 2004Assignee: Hoffman-La Roche Inc.Inventors: Synese Jolidon, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
-
Patent number: 6756380Abstract: Compounds of the general formula are described: wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R4/R4′are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; R6 is hydrogen; R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon rinType: GrantFiled: May 22, 2000Date of Patent: June 29, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Michael Bös, Guido Galley, Thierry Godel, Torsten Hoffmann, Walter Hunkeler, Patrick Schnider, Heinz Stadler
-
Patent number: 6756374Abstract: Disclosed are novel diaminothiazoles of formula wherein R1, R2, R3, R4 and R5 are as herein disclosed. These compounds and their pharmaceutically acceptable salts and esters are selective inhibitors of Cdk4. As such, these compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and their pharmaceutically acceptable salts and esters, as well as intermediates useful in the preparation of the compounds of formula I.Type: GrantFiled: January 9, 2002Date of Patent: June 29, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Li Chen, Qingjie Ding, Paul Gillespie, Kyungjin Kim, Allen John Lovey, Warren William McComas, John Guilfoyle Mullin, Jr., Agostino Perrotta
-
Patent number: 6747026Abstract: Compounds of the invention are amine oxide prodrugs showing activity on the NK1 receptor.Type: GrantFiled: January 7, 2003Date of Patent: June 8, 2004Assignee: Hoffman-La Roche Inc.Inventors: Torsten Hoffmann, Sonia Maria Poli, Patrick Schnider, Andrew Sleight
-
Patent number: 6743789Abstract: The present invention is a compound of formula The compound and derivatives or pharmaceutically acceptable salts thereof of the invention have a good affinity and selectivity to the GABA A &agr;5 receptor and are useful for the treatment of diseases related to this receptor.Type: GrantFiled: November 8, 2001Date of Patent: June 1, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Raffaello Masciadri, Andrew William Thomas, Juergen Wichmann
-
Patent number: 6740760Abstract: New compounds have the formula: wherein R, R1, X and Y have the meanings described herein. Methods are set forth for synthesizing these compounds and using these compounds to treat diseases associated with amyloidosis, such as Alzheimer's disease, maturity onset diabetes mellitus, familial amyloid polyneuropathy, scrapie, and Kreuzfeld-Jacob disease.Type: GrantFiled: July 1, 2002Date of Patent: May 25, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Cornelia Hertel, Torsten Hoffmann, Roland Jakob-Roetne, Roger David Norcross
-
Patent number: 6737409Abstract: Novel anti-tumor compounds of formula, are disclosed. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), the use of compounds of formula (I) for the treatment of cancer, and processes for the preparation of compounds (I).Type: GrantFiled: July 15, 2002Date of Patent: May 18, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Toshihiko Fujii, Takehiro Okada, Mikio Taniguchi, Fumio Watanabe